Felicity Thomas

Technical advances in process understanding and control must be accompanied by a change in mindset.

Political instability is causing uncertainty in Europe and wreaking havoc with US regulatory timeframes.

A new initiative has been launched to help stimulate industry discussion on innovative tech for use across the drug supply chain.

The EU FMD deadline is closing in, so now is the time to look beyond the short term.

The new year has started with a bang in terms of mergers and acquisitions.

Early adoption of the right approach to address solubility can deliver significant benefits.

New approaches seek to address formulation and delivery challenges for these complex molecules.

As Brexit rapidly approaches, the lack of clarity around the regulatory balance between the regions could lead to a reduction in standards.

A brief preview of what to expect at pharma’s dedicated packaging and drug delivery event.

Taking stock on the ‘big-ticket’ news items, both good and bad, from the past 12 months.

During CPhI Worldwide in Madrid, Lynne Byers, executive director of NSF International detailed the facts about how Brexit can impact the pharmaceutical industry.

… Brexit may be a bumpy ride. Here, the new European editor of the PharmTech Group, Felicity Thomas, discusses Brexit and its implications for the pharma industry.